Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.32+0.02 (+1.54%)
Close on Nov 20, 2026Market cap $184.19MP/E –Yield –
Inhibikase Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Inhibikase Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$42.61M. For fiscal 2025 it was -$27.80M. The highest annual figure on record is -$14.30M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$27.80M | – |
| FY2024 | Dec 31, 2024 | -$19.15M | – |
| FY2023 | Dec 31, 2023 | -$18.10M | – |
| FY2022 | Dec 31, 2022 | -$17.59M | – |
| FY2021 | Dec 31, 2021 | -$14.30M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.06M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.52M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.44M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.70M | – |
See a number that looks wrong?